Funding: Alfa Wassermann.
INTRODUCTION
Due to its relatively low cost and favorable efficacy/safety profile, methotrexate (MTX) is currently considered the drug of choice for treating rheumatoid arthritis (RA), both as first-line monotherapy in treatment-naive patients [1] [2] [3] [4] , and as an anchor drug, in MTX-insufficient responders, in combination with other conventional (csDMARDs) or biological disease-modifying antirheumatic drugs (bDMARDs) [3] [4] [5] .
MTX optimization is therefore fundamental in the effective management of patients with RA.
In this respect there are several aspects of utmost importance, such as the starting and target doses of MTX, the best treatment strategy [6] [7] [8] , and the optimal route of administration [9, 10] . In fact, the choice of MTX route of administration might significantly affect drug bioavailability, thus influencing both its efficacy and tolerability. The aim of this article is to review the available evidence on differences in the pharmacological characteristics and corresponding clinical effects of oral (MTX OR) and subcutaneous MTX (MTX SC) in patients with RA. This review is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
SEARCH METHODS
The PubMed and Medline databases were searched up to November 1, 2015 to identify publications on the use of oral and subcutaneous MTX usage in RA. A combination of relevant keywords including methotrexate, subcutaneous route, oral route, rheumatoid arthritis, treatment, pharmacokinetic, efficacy and toxicity were used (Table 1) . Publications were hand searched and selected for inclusion in the review based on the authors experience in the field (Table 2 ).
In particular, the references were first selected from title and abstract, then included or discarded after reading the full text. The main inclusion criteria were studies comparing MTX SC versus MTX OR in patients with RA.
BIOAVAILABILITY
The existence of different routes of MTX administration (oral and parenteral) has led to the conduction of pharmacokinetic studies designed to compare and highlight any significant differences in the drug's therapeutic impact. Several studies have demonstrated higher bioavailability at various dosages with MTX SC than with MTX OR ( [8] . A post hoc analysis of this study, focused on the switch from MTX OR to MTX SC, specifically in the subset of patients originally assigned to the intensive strategy, has been published [15] .
Data from 57 of the 151 patients originally randomized to the intensive therapy arm were analyzed: 21 patients switched from MTX OR to MTX SC due to adverse events and 36 patients switched due to inadequate clinical efficacy.
Regardless of the reason for switching, a statistically significant reduction in the mean value of DAS28 was seen 1 month after the switch, and for up to 4 months of evaluation (P\0.05; Table 5 ).
The benefits of switching MTX route of administration, from oral to parenteral, have (Table 4) , with a significantly higher probability of obtaining DAS28 clinical remission (odds ratio 1.15; 95% CI 1.05-1.25; P = 0.002).
DISCUSSION
Bioavailability data discussed herein are reflected in the latest Italian recommendations and guidelines on the management of RA [7, 22] . While guidelines permit a broad therapeutic range (7.5-25.0 mg/week), the optimal treatment strategy requires initial doses higher than those recommended in the past (12.5-15.0 mg/week). In addition, a specific focus on MTX administered parenterally has been added, with guidelines recommending MTX SC both as first-line therapy and in patients refractory to MTX OR, to ensure higher bioavailability and thus achieve greater clinical efficacy. 
CONCLUSIONS
In conclusion, in accordance with the latest scientific evidence on the topic of MTX and RA, we might consider the following observations: 1. From a pharmacokinetic standpoint, at the same dosage, MTX SC has a significantly higher bioavailability with respect to the oral route of administration. This difference is even more pronounced for medium-to-high dosages (i.e., [15 mg/week 13. Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses C15 mg may be
